Condition
Scarring Alopecia
Total Trials
6
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
Early P 1 (1)
Trial Status
Completed3
Recruiting2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06946550Not ApplicableRecruitingPrimary
Non-Ablative Laser to Treat Scarring Alopecia With Hair Follicle Gene Expression Analysis
NCT05460611Not ApplicableRecruitingPrimary
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
NCT06512766Completed
a Retrospective Study on the Systemic Treatment of LPP and FFA
NCT03346668Early Phase 1CompletedPrimary
Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
NCT03078686Not ApplicableUnknown
Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata
NCT03044782CompletedPrimary
Barriers to Care and QOL for CCCA Patients
Showing all 6 trials